Rare Disease Drug Commercialization With Zevra Therapeutics' Neil McFarlane

About this episode

Neil McFarlane discusses the transition of Zevra Therapeutics into a focused rare disease company and the importance of patient advocacy and AI in identifying patients.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Neil McFarlane, CEO at Zevra Therapeutics, talks about transitioning to a focused rare disease company through acquisitions, and building out a commercial organization. Neil explains the importance of working with rare disease patient advocacy groups, using AI to analyze electronic health records and claims data to identify and diagnose patients with Niemann-Pick disease type C, and adap...

People in this episode

Host: Ben Comer

Guest: Neil McFarlane

Topics covered

• rare disease
• drug commercialization
• patient advocacy
• AI in healthcare
• health records analysis

Keywords

• rare disease
• drug commercialization
• Zevra Therapeutics
• Niemann-Pick disease
• AI
• patient advocacy
• health records

Mentioned in this episode

Organizations: Zevra Therapeutics

Products: Niemann-Pick disease type C

More episodes of Business Of Biotech

• The Editors' Roundtable: A Midyear Look At The 2026 Life Sciences Industry · June 8, 2026 · 1h 24m
• Derisking CNS Drug Development With Tortugas Neuroscience's Jeff Jonas, M.D. · June 1, 2026 · 50 min
• Scaling Manufacturing For Personalized Cell Therapies With Cellino's Marinna Madrid, Ph.D. · May 18, 2026 · 51 min
• Building A New Antibody Discovery Platform With Infinimmune's Wyatt McDonnell, Ph.D. · May 11, 2026 · 54 min
• From Partnered ASO Therapies To A Wholly-Owned Pipeline With Ionis's Brett Monia, Ph.D. · May 4, 2026 · 56 min
• Implementing A New CEO Strategy With NervGen's Adam Rogers, M.D. And Rich Macary · April 27, 2026 · 48 min